HumuLIN R U-500 insulin dosage errors

The Institute for Safe Medication Practices continues to receive reports of dose measurement confusion with HumuLIN R U-500 concentrated insulin injection, according to a recent safety alert from the agency. » Full article

Telmisartan, valsartan for diabetes

Telmisartan and valsartan, used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke, or heart failure, according to a study published on the Canadian Medical Association Journal.
» Full article

EHR adoption

The use of electronic health records saved more than 3% in ambulatory health costs but did not reduce overall inpatient costs, according to a new study. » Full article

Continuing Education

Pain Management: New July CPE activity available

Welcome to our CPE series: Pain Management Considerations for Medication Therapy Management, which has been designed for pharmacists who take care of patients who need pain relief. You can earn up to 10 credits by completing our April 2013 through August 2013 monthly knowledge-based activities and 2 credits from September 2013 to October 2013 with 2 monthly interactive online case studies.

The July activity covers regulatory and ethical issues in pain management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

Current trends in specialty drug utilization and management: Payer interventions in the shadow of a burgeoning pipeline

Specialty pharmaceuticals are continuing to play an increasingly large role in managed care plan budgets and are certainly deserving of the increased payer attention they are receiving, according to a recent trend report. » Full article

• High cost, renal complications in diabetes management

• Pharmacist-physician collaborative care effective in T2DM

• CPOE systems

• When it comes to safe and reliable biological medicines, manufacturing matters

SURVEY

With a third new oral agent (Tecfidera) recently introduced for relapsing-remitting MS, how will the MS market look in the next 3-5 years?

— Orals will become the most frequently prescribed products

— Injectables will continue to dominate market share

— Equal split between orals and injectables

Click Here to let us know.

RESOURCES

Drug Watch

Latest Clinical News